Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

The Clorox Company CLX

Consumer Defensive — Household & Personal Products
S&P 500 Member Dividend Aristocrat Insider Buys (last 12m)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.85
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — — — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership
1.29%

Capital & Financial Ratios

Market Cap
10,330.00
Revenue
6,720.00
Net Income
601.00
Free Cash Flow
405.00
Net Debt
3,839.00
Current Ratio
0.66
Debt/Equity
15.80
P/E ratio
17.24
P/S ratio
1.51
P/B ratio
40.16
Past 5Y EPS Growth
(18.70%)
This Y EPS Growth
4.68%
Next Y EPS Growth
7.89%
Next 5Y EPS Growth
5.89%
in millions of $

Dividends

Payout Ratio
3.93
Annual Dividend Rate
4.76
Annual Dividend Yield
3.13%
total individual payouts
2029 ‡‡‡‡‡
2028 ‡‡‡‡
2027 ‡‡‡‡‡
2026 5.00
—
—
—
2025 4.92
—
—
—
—
2024 4.84
—
—
—
—
2023 4.76
—
—
—
—
2022 4.68
—
—
—
—
2021 4.54
—
—
—
—
2020 4.34
—
—
—
—
2019 4.04
—
—
—
—
2018 3.72
—
—
—
—
2017 3.28
—
—
—
—
2016 3.14
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 2026
Cash 367.00 202.00 167.00 143.00
Receivables 688.00 695.00 821.00 791.00
Inventory 696.00 637.00 523.00 777.00
Other 77.00 — — —
1,828.00 1,622.00 1,608.00 1,824.00
2023 2024 2025 2026
Payables 1,659.00 1,486.00 1,828.00 1,600.00
ST’ Debt 146.00 — — 1.00
Other 629.00 — — —
1,917.00 1,574.00 1,919.00 2,773.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Sep Dec Mar Jun Year
’26 — — — —
—
’26 1,429.00 1,673.00 1,670.00 1,948.00
6,720.00
’25 1,762.00 1,686.00 1,668.00 1,988.00
7,104.00
’24 1,386.00 1,990.00 1,814.00 1,903.00
7,093.00
’23 1,740.00 1,715.00 1,915.00 2,019.00
7,389.00
’22 1,806.00 1,691.00 1,809.00 1,801.00
7,107.00
’21 1,916.00 1,842.00 1,781.00 1,802.00
7,341.00
in millions of $

Operating Cash Flow

Sep Dec Mar Jun Year
’26 — — — —
—
’26 93.00 311.00 (122.00) 330.00
612.00
’25 221.00 180.00 286.00 294.00
981.00
’24 20.00 153.00 182.00 340.00
695.00
’23 178.00 209.00 341.00 430.00
1,158.00
’22 41.00 181.00 229.00 335.00
786.00
’21 383.00 246.00 264.00 383.00
1,276.00
in millions of $

Free Cash Flow

Sep Dec Mar Jun Year
’26 — — — —
—
’26 57.00 269.00 (165.00) 244.00
405.00
’25 182.00 127.00 233.00 219.00
761.00
’24 (4.00) 101.00 127.00 259.00
483.00
’23 132.00 167.00 285.00 346.00
930.00
’22 (11.00) 124.00 166.00 256.00
535.00
’21 314.00 164.00 183.00 284.00
945.00
in millions of $

EPS

Sep Dec Mar Jun Year
’26 — — — —
—
’26 0.65 1.29 1.54 1.34
4.81
’25 0.80 1.54 1.50 2.68
6.52
’24 0.17 0.75 (0.41) 1.73
2.25
’23 0.68 0.80 (1.71) 1.42
1.20
’22 1.14 0.56 1.21 0.81
3.73
’21 3.22 2.03 (0.49) 0.78
5.58

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

3.2
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 120.50 114.69 127.60 96.66 83.09 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 186.86 178.21 171.37 164.22 128.90 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9,000 8,700 8,000 7,600 9,200 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.79 0.85 0.89 0.93 0.73 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7,107.00 7,389.00 7,093.00 7,104.00 6,720.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.81% 39.36% 42.97% 45.23% 42.32% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 607.00 238.00 398.00 1,078.00 791.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.54% 3.22% 5.61% 15.17% 11.77% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 471.00 161.00 292.00 824.00 601.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 224.00 681.00 235.00 219.00 247.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 57.73 59.79 57.12 57.51 55.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.75 1.21 2.26 6.56 4.82 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.38 9.37 5.60 7.94 5.03 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.04) (1.84) (1.71) (1.78) (1.70) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.35 7.52 3.89 6.16 3.33 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.92 3.14 3.96 3.90 2.07 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 123.11 123.59 124.17 123.53 121.78 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.70 130.36 59.66 18.30 19.80 ‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.44 2.66 2.35 2.09 1.73 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.81 50.66 33.88 30.77 46.12 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.81 2.97 2.73 2.48 2.30 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.32 23.56 40.13 23.11 38.18 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 786.00 1,158.00 695.00 981.00 612.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (251.00) (228.00) (212.00) (220.00) (207.00) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 535.00 930.00 483.00 761.00 405.00 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (59.00) (89.00) 48.00 (311.00) (949.00) — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,795.00 2,623.00 2,481.00 2,484.00 3,982.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,612.00 2,256.00 2,279.00 2,317.00 3,839.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 729.00 388.00 492.00 482.00 252.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.40% 2.46% 4.79% 14.32% 8.79% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.03% 9.64% 11.55% 24.12% 13.95% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 69.95% 26.68% 63.64% 166.32% 159.95% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Clorox (CLX), a Dividend Aristocrat in consumer staples, has weathered a decade of extremes—from COVID-driven revenue peaks at $7.34 billion in 2021 to a devastating 2023 cyberattack that slashed earnings 74% and exposed operational vulnerabilities. Shares now trade midway in their multi-year range, reflecting stabilized post-pandemic sales around $7 billion but persistent profitability swings from input inflation and consumer shifts. While efficiency gains shine—revenue per employee up 30% via headcount cuts and buybacks—gross margins’ rebound to 45% projected for 2025 offers a buffer, echoing resilient peers like Procter & Gamble in tougher times.

The balance sheet remains a stronghold, with steady $2.5 billion debt, positive equity, and free cash flow poised to recover 57% to $761 million in 2025, funding reliable dividends amid capex-light operations. Valuation looks compelling: projected PE at 18.3 below sector norms, EV/sales at 2.48 implying a 20-25% discount to historical averages, though ROIC’s tripling to 24% hinges on execution. Insider buys signal conviction, offsetting routine sells.

Analysts forecast a cautious 2026 revenue dip of 8% before modest rebounds, with EPS growth at 5% CAGR—prudent amid spending slowdown risks and 3.5x debt leverage. Yet, if margins hold above 45% and disruptions abate, 15-20% upside potential lurks, rewarding patient accumulators of dips in this cyclical staple. Full analysis unpacks the charts and scenarios.

Read full commentary →

The Clorox Company (CLX) Latest News

News by impact score

Fine-tune

16 Sep

3 , 12:40 PM
Clorox pursues strategic initiatives alongside pricing strength to drive growth amid competitive pressures. Strategic initiatives and pricing actions point to moderate effects on financial performance without fundamentally shifting long-term trajectory.

3 Sep

3 , 10:47 AM
Inflation pressures Clorox margins while cost savings initiatives aim to limit erosion and sustain profitability. Inflation offset efforts can influence Clorox financial results and near-term investor sentiment.

21 Aug

3 , 2:21 PM
GOJO could influence Clorox's fiscal 2027 growth rates and profit margins through strategic or operational developments. GOJO involvement points to moderate effects on Clorox's long-term financial trajectory and positioning.

3 , 1:56 PM
GOJO growth meets margin pressure at Clorox, raising questions on whether CLX stock is worth buying. GOJO growth offset by margin pressure can influence Clorox financial results and stock trajectory.

11 Aug

3 , 9:17 PM
Analysts raised five key questions on Clorox’s Q2 earnings call covering sales trends, margin pressures, brand performance and outlook. Earnings-call questions highlight near-term operational and competitive issues that can shift short-term sentiment without altering long-term trajectory.

3 transcript www.fool.com, 10:49 AM
Clorox (CLX) reported Q4 2026 results in its earnings call, covering sales, margins, segment performance, and management outlook on costs and growth. Quarterly earnings and guidance typically produce moderate shifts in valuation and near-term sentiment.

3 www.supplychaindive.com, 8:39 AM
Clorox states its ERP transition will deliver supply chain gains this year. ERP transition is expected to improve supply chain operations and modestly support financial performance.

10 Aug

3 www.supplychaindive.com, 3:29 AM
Clorox expects a $200M inflation hit with supply chain costs as a contributing factor. Expected $200M inflation costs will pressure Clorox margins and near-term earnings.

5 Aug

3 , 5:15 PM
Clorox reports 14% sales growth amid persistent headwinds expected through fiscal 2027. Sales growth signals positive momentum while extended headwinds cap long-term trajectory.

4 Aug

4 app.moby.co, 8:30 AM
The Clorox Company held its Q4 2026 earnings call covering financial results and outlook. Earnings call details and guidance typically drive immediate stock moves and valuation shifts for Clorox.

3 , 12:21 PM
Clorox faces weak demand and cost pressure, RBC reports. Weak demand and cost pressures signal moderately noticeable effects on Clorox financial performance.

3 , 11:14 AM
Clorox Q4 earnings and sales beat estimates with GOJO contributions supporting results. Q4 beat offers moderate positive signal on near-term results but no fundamental trajectory change.

3 , 10:00 AM
Clorox Q4 earnings call highlighted persistent inflation pressures alongside building share recovery momentum. Q4 earnings details on inflation and recovery point to noticeable but not transformative shifts in company outlook.

3 qz.com, 9:26 AM
Clorox fiscal 2027 outlook faces pressure from persistent inflation and consumers shifting toward value options. Inflation and value shopping trends may moderately influence Clorox financial performance and positioning.

3 Aug

4 , 4:10 PM
Clorox reported Q4 and FY26 results and issued FY27 outlook. Quarterly results plus forward outlook directly shape investor views and valuation.

3 transcript www.marketbeat.com, 8:03 PM
Clorox Q4 earnings call highlighted financial results, revenue figures, earnings per share, and forward guidance. Q4 earnings details can moderately shift investor sentiment and near-term stock movement.

3 , 7:30 PM
Clorox Q4 earnings metrics are compared directly to Wall Street estimates. Standard Q4 earnings metric comparison offers routine insight into results without signaling major strategic or market shifts.

3 , 2:23 PM
CLX stock offers low valuation but faces debt and execution risks, raising doubts on its attractiveness as a buy. Debt and execution risks may moderately influence CLX financial performance and market sentiment.

2 Aug

3 , 6:15 PM
Clorox prepares to release Q2 earnings with investor attention on sales growth, margins, and updated guidance. Quarterly earnings previews set expectations that can move the stock ahead of results.

29 Jul

4 , 1:07 AM
Clorox issues softer earnings outlook accompanied by bearish analyst commentary that pressures shareholder value and signals revised expectations for future performance. Softer earnings outlook and bearish analyst tone directly reshape investor views and company valuation trajectory.

3 , 10:10 AM
Clorox (CLX) stock may be 32% undervalued despite margin risks. Valuation estimates and margin risks can shift CLX stock trajectory and investor sentiment moderately.

3 , 2:08 AM
Clorox (CLX) encounters earnings pressure with questions over whether the stock is fully valued. Earnings pressure and valuation concerns may moderately influence Clorox stock performance and sentiment.

27 Jul

3 , 10:00 AM
Clorox Q4 earnings expected to decline. Expected Q4 earnings decline may pressure Clorox stock and near-term sentiment.

14 Jul

3 , 9:32 AM
Clorox household segment shows strength but questions persist on whether it can sustain overall company growth. Household segment analysis signals moderate effects on Clorox financial performance and growth outlook.

13 Jul

3 www.trefis.com, 6:35 PM
Evidence on The Clorox Company (CLX) leans toward it being a value trap with questionable upside despite apparent valuation metrics. Analysis labeling CLX a potential value trap can shift investor views and near-term trading patterns without altering core operations.

11 Jul

4 , 9:11 AM
Clorox lowered its 2026 outlook amid persistent cost pressures, altering the company's investment narrative and growth expectations. Lowered 2026 outlook and cost pressures point to material headwinds that can shift Clorox's valuation and investor sentiment.

4 , 2:14 AM
Clorox cut its guidance ahead of earnings, prompting questions on whether the stock is undervalued. Guidance cuts directly lower expectations and can materially shift Clorox's near-term stock trajectory and sentiment.

17 Jun

3 , 4:15 PM
Clorox simplifies operating structure to improve execution and accelerate growth. Structural simplification targets better execution and faster growth but effects remain unproven and potentially limited.

2 Jun

4 PR Newswire, 9:00 AM
Clorox Healthcare launches two breakthrough innovations to address infection prevention challenges in healthcare settings. Breakthrough product launches in core infection control segment can drive revenue growth and strengthen market positioning.

31 May

3 Simply Wall St., 4:02 AM
Clorox initiates CEO search, placing leadership transitions and ongoing recovery efforts in focus. CEO search during recovery may affect strategic direction and market sentiment without fundamentally altering long-term trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us